Stephanie van Hoppe

142 Chapter 6 Figure 3: Impact of mouse and human OATP1A/1B transporters on the plasma and liver disposition of various anti-cancer drugs. Plasma disposition ( A, C, and E ) and liver-to-plasma ratios ( B, D, and F ) of docetaxel, SN-38 and doxorubicin are shown in the figure at various time points after i.v. administration of 10 mg/kg docetaxel, 10 mg/kg irinotecan (pro-drug of SN-38) or 5 mg/kg of doxorubicin, respectively. Drugs were administered to wild-type and Oatp1a/1b(-/-) mice, and to OATP1B1-, OATP1B3-, and OATP1A2-transgenic mice in an Oatp1a/1b(-/-) background. Data are presented as mean ± SD [*, P < 0.05; **, P < 0.01; ***, P < 0.001 when compared with wild-type; # , P < 0.05; ## , P < 0.01; ### , P < 0.001 when compared with Oatp1a/1b(−/−) mice]. Note that different units are used to indicate the plasma concentrations of each drug. This figure was modified with permission from previously published experimental data of Iusuf et al. (2015; 2014) and Durmus et al. (2014). Figure 3 - Impact of mouse and human OATP1A/1B transporters on the plasma and liver disposition of various anti-cancer drugs. Plasma disposition ( A, C, and E ) and liver-to-plasma ratios ( B, D, and F ) of docetaxel, SN-38 and doxorubicin are shown in the figure at various time points after i.v. administration of 10mg/kg docetaxel, 10mg/kg irinotecan (pro-drug of SN-38) or 5mg/kg of doxorubicin, respectively. Drugs were administered to wild-type and Oatp1a/1b(-/-) mice, and to OATP1B1-, OATP1B3-, and OATP1A2-transgenic mice in an Oatp1a/1b(-/-) background. Data are presented as mean ± SD [*, P < 0.05; **, P < 0.01; ***, P < 0.001 when compared with wild-type; # , P < 0.05; ## , P < 0.01; ### , P < 0.001 when compared with Oatp1a/1b(−/−) mice]. Note that different units are used to indicate the plasma concentrations of each drug. This figure was modified with permission from previously published experimental data of Iusuf et al. (2015; 2014) and Durmus et al. (2014).